Does PSA screening save lives? disputed

Positions

1. Yes: ERSPC

   The European trial found fewer prostate cancer deaths with screening: rate ratio 0.80 at a median of nine years (2009) and again 0.80 at 16 years, when 570 men had to be invited and 18 diagnosed to prevent one death.

   Sources

   1. National Cancer Institute PDQ: Prostate cancer screening (health professional version) Secondary

2. No clear benefit: PLCO

   The American trial of 76,693 men found no reduction in prostate cancer deaths in 2009, and a rate ratio of 0.93 at about 17 years. Its comparison arm was heavily tested, so it compared screening with less screening.

   Sources

   1. National Cancer Institute PDQ: Prostate cancer screening (health professional version) Secondary

3. Against routine screening (USPSTF 2012)

   The Task Force recommended against PSA-based screening at all ages (grade D) on 15 May 2012.

   Sources

   1. USPSTF 2012 recommendation: prostate cancer screening Primary

4. An individual decision (USPSTF 2018)

   On 8 May 2018 the Task Force made screening an individual decision for men aged 55 to 69 (grade C), keeping grade D for men of 70 and over.

   Sources

   1. USPSTF 2018 recommendation: prostate cancer screening Primary

5. A test that does harm

   Richard Ablin, credited with discovering a prostate antigen, argued in 2014 that the FDA had failed the public by allowing routine screening.

   Sources

   1. Wikipedia: Richard J. Ablin Secondary

Evidence

Stamey's 1987 paper already found PSA raised in 86% of men with benign enlargement and called neither marker specific. The number needed to screen in the 2009 ERSPC report is itself disputed between sources (1,410 screened and 48 additionally treated, against 781 invited and 48 biopsied). An autopsy study cited by the NCI found occult prostate cancer in nearly 60% of men over 80, the root of overdiagnosis.

Current standing

Unresolved. The USPSTF update is in progress, a 2026 Cochrane update concludes that screening likely reduces prostate cancer mortality (one secondary source), and MRI before biopsy and active surveillance are changing the balance of harms. As the film puts it, the conversation is still going on.

All sources